BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KIMMTRAK (tebentafusp-tebn) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KIMMTRAK (tebentafusp-tebn)\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05785754-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 1 readout est. (NCT05785754)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 1.\nStudy: DCSZ11 as a Mono
 therapy and in Combination in Patients With Advanced or Metastatic Solid T
 umors\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05785754
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05315258-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT05315258)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Melanoma.\nStudy: Teben
 tafusp in Molecular Relapsed Disease (MRD) Melanoma\nEstimated primary com
 pletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tebentafusp-tebn#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05315258
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06414590-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06414590)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Neoadjuvant Tebentafusp for Uveal Melanoma\nEstimated primary completion:
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tebenta
 fusp-tebn#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06414590
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057596-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT07057596)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07057596
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627244-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06627244)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Study of Tebentafusp and Radioembolization in the Treatment of Metastatic
  Uveal Melanoma\nEstimated primary completion: 17 February 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06627244
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549297-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT05549297)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Melanoma.\nStudy: Teben
 tafusp Regimen Versus Investigator's Choice in Previously Treated Advanced
  Melanoma (TEBE-AM)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05549297
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06070012-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06070012)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal 
 Melanoma\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06070012
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06626516-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 1/2 readout est. (NCT06626516)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 1/2\, Uveal Melanoma.\nStud
 y: Tebentafusp-tebn With LDT in Metastatic UM\nEstimated primary completio
 n: October 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tebe
 ntafusp-tebn#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06626516
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942442-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT06942442)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2.\nStudy: A Phase II Trial
  of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell 
 Sarcoma\nEstimated primary completion: 1 October 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06942442
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276386-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 2 readout est. (NCT07276386)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 2\, Uveal Melanoma.\nStudy:
  Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Me
 tastatic Uveal Melanoma\nEstimated primary completion: December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tebentafusp-tebn#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07276386
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246149-10942@assetmemo.bio
DTSTAMP:20261121T005445Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:KIMMTRAK (tebentafusp-tebn): Phase 3 readout est. (NCT06246149)
DESCRIPTION:KIMMTRAK (tebentafusp-tebn)\, phase 3\, Uveal Melanoma.\nStudy:
  Adjuvant Tebentafusp in High Risk Ocular Melanoma\nEstimated primary comp
 letion: November 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tebentafusp-tebn#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06246149
URL:https://assetmemo.bio/drug/tebentafusp-tebn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
